{"ok":true,"trend":{"id":208195,"platform":"news","region":"global","key":"the willow trial didn’t fail enpatoran. the endpoint did.","title":"The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.","url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOWs3QXBscDRyd0l6TzRJSlhubDRLcTdBRVY3bnFnZFJ5NUNXZ001czNVWGVrYmZjN0VCVnI4Wk1oSWZ2ZU1FYVc5WFJTcWV0c0lvNVVOVTRpdVZFdF9CQnlGQ0xaZTlIRmhyem1uYTk4LU9qSlFEUzFkSTlER0xrSUN1UE5ZbERPREc2eFh2YmJvRHQ2TlY5Qk9Wb1FHVGREREVVZ291YzdEaENMdGtrWXBCZ2k1bjFBSEEw?oc=5","first_seen":"2026-09-28T07:48:45.607113Z","last_seen":"2026-09-28T10:32:46.568837Z","last_rank":37,"peak_rank":37,"last_volume":null,"peak_volume":0,"seen_count":3,"score":0.6415625,"category_hint":"medicine","section":"health","category":"medicine","summary":"Commentary around Merck KGaA's enpatoran is challenging the framing of the WILLOW trial results, arguing the drug was not proven ineffective but that the trial's chosen endpoint failed to capture the treatment effect. The piece says the outcome measure, not the therapy itself, is what fell short, reigniting debate over how lupus clinical trials are designed and judged.","why":"The trial's results are fresh news and the contrarian endpoint argument is fueling debate among clinicians and investors.","tone":"mixed","entities":["Enpatoran","WILLOW trial","Merck KGaA","lupus"],"summarized_at":"2026-09-28T07:49:01.343483Z","meta":{"via":"scan","lang":"en","term":"clinical trial","source":"The Clinical Trial Vanguard","generic":0.04,"published":"Mon, 28 Sep 2026 07:33:52 GMT"},"nw":0.39,"promo":0.03,"kind":"news_event","importance":1.46,"hidden":false,"hide_reason":null,"judged_at":"2026-09-28T07:48:45.964099Z","title_en":"Analysts Argue WILLOW Trial Endpoint, Not Enpatoran, Failed","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-28T07:48:45.607113Z","rank":37,"volume":null},{"captured_at":"2026-09-28T09:10:46.558339Z","rank":37,"volume":null},{"captured_at":"2026-09-28T10:32:46.568837Z","rank":37,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOWs3QXBscDRyd0l6TzRJSlhubDRLcTdBRVY3bnFnZFJ5NUNXZ001czNVWGVrYmZjN0VCVnI4Wk1oSWZ2ZU1FYVc5WFJTcWV0c0lvNVVOVTRpdVZFdF9CQnlGQ0xaZTlIRmhyem1uYTk4LU9qSlFEUzFkSTlER0xrSUN1UE5ZbERPREc2eFh2YmJvRHQ2TlY5Qk9Wb1FHVGREREVVZ291YzdEaENMdGtrWXBCZ2k1bjFBSEEw?oc=5","author":"The Clinical Trial Vanguard","title":"The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.","snippet":null,"posted_at":"2026-09-28T07:33:52Z","likes":null}],"elsewhere":[],"window":"7d"}}